7. Other operating income/(expense)
| 2017 | 2016 | 2015 | ||||||||||
| £m | £m | £m | ||||||||||
|
Impairment of equity investments |
(30 | ) | (47 | ) | (263 | ) | ||||||
|
Disposal of equity investments |
37 | 254 | 342 | |||||||||
|
Disposal of businesses and assets |
195 | 283 | 9,661 | |||||||||
|
Fair value remeasurements on contingent consideration recognised in business combinations |
(1,012 | ) | (2,205 | ) | (1,965 | ) | ||||||
|
Remeasurement of ViiV Healthcare put option liabilities and preferential dividends |
13 | (577 | ) | – | ||||||||
|
Remeasurement of Consumer Healthcare put option liability |
(1,186 | ) | (1,133 | ) | (83 | ) | ||||||
|
Fair value adjustments on derivative financial instruments |
9 | (3 | ) | 2 | ||||||||
|
Other income/(expense) |
9 | 23 | 21 | |||||||||
|
|
|
|
|
|
|
|||||||
| (1,965 | ) | (3,405 | ) | 7,715 | ||||||||
|
|
|
|
|
|
|
|||||||
Disposal of businesses and assets in 2017 included a profit of £250 million on the disposal of the anaesthesia business to Aspen. Disposals in 2016 included milestone income of £152 million in relation to the divestment of ofatumumab and a number of other smaller divestments and in 2015 included the disposal of the Oncology business to Novartis for £9,228 million and an initial £200 million for the divestment of ofatumumab.
Fair value remeasurements on contingent consideration recognised in business combinations included £909 million related to the acquisition of the former Shionogi-ViiV Healthcare joint venture and £53 million payable to Novartis related to the Vaccines acquisition. The fair value remeasurements on contingent consideration, the remeasurement of ViiV Healthcare put option liabilities and preferential dividends and the remeasurement of Consumer Healthcare put option liability include the additional charge arising from US tax reform of £666 million.